These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3552366)

  • 1. Absorption kinetics and action profiles of intermediate acting human insulins.
    Bilo HJ; Heine RJ; Sikkenk AC; van der Meer J; van der Veen EA
    Diabetes Res; 1987 Jan; 4(1):39-43. PubMed ID: 3552366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and miscibility of 4 highly purified porcine insulins: a study in vitro and in healthy volunteers.
    Heine RJ; Van der Stap H; Salemink PJ; Kolkman-Roodbeen JC; Banken P; Gribnau TC; van der Veen EA
    Diabetes Res; 1987 Jan; 4(1):45-50. PubMed ID: 3552367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Action profile of a semisynthetic human isophane zinc insulin compared with customary isophane insulin].
    Gin H; Delafaye C; Morlat P; Aubertin J
    Diabete Metab; 1992; 18(6):445-50. PubMed ID: 1297601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
    Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
    Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the activity of Rapitard and Actraphane insulins.
    Colagiuri S; Jones S
    Diabete Metab; 1988 Dec; 14(6):689-92. PubMed ID: 3073090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action profile of human ultralente insulin compared with human NPH-insulin].
    Starke AA; Heinemann L; Hohmann A; Berger M
    Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
    Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
    Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
    Saner B; Fankhauser S
    Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
    Olsson PO; Hans A; Henning VS
    Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of a semi-synthetic human insulin preparation (30/70 NPH insulin Organon): comparison with another 30/70 NPH (Actraphane Novo).
    Gin H; Nivet AM; Morlat P; Aubertin J
    Diabete Metab; 1989; 15(5):247-50. PubMed ID: 2698366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
    Duchateau J; Schreyen H; Dorchy H
    Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects.
    Burke B; Andrews WJ; Hadden DR
    Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of mixing regular- and intermediate-acting insulins on their absorption and biological activity.
    Schulz B; Menzel R; Besch W
    Exp Clin Endocrinol; 1988 Mar; 91(1):27-34. PubMed ID: 3286272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of five pre-mixed combinations of 'short-' and 'intermediate-acting' (NPH) insulins in healthy subjects following subcutaneous administration.
    Owens DR; Jones AL; Dolben J; Dean JD; Petocz P; Coates PA; Luzio SD
    Diabetes Res; 1993; 22(2):77-86. PubMed ID: 8205740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting insulin analogs.
    Rosskamp RH; Park G
    Diabetes Care; 1999 Mar; 22 Suppl 2():B109-13. PubMed ID: 10097910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From the concept of fast acting analogs to the properties of the insulin Lispro].
    Selam JL
    Diabetes Metab; 1997 Sep; 23 Suppl 3():45-9. PubMed ID: 9410552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures.
    Davis SN; Thompson CJ; Brown MD; Home PD; Alberti KG
    Diabetes Res Clin Pract; 1991 Aug; 13(1-2):107-17. PubMed ID: 1773708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
    Rolla A
    Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and urine kinetics of erythritol after oral ingestion by healthy humans.
    Bornet FR; Blayo A; Dauchy F; Slama G
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 2):S280-5. PubMed ID: 8933644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.